Offer - Urjas Oil for just ₹ 1
Oflaquin M is an allopathic medicine The correct dosage of Oflaquin M depends on the patient's age, gender, and medical history. This information has been provided in detail in the dosage section.
Oflaquin M is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
Is the use of Oflaquin M safe for pregnant women?
There are no side effects of Oflaquin M in pregnant women.
Is the use of Oflaquin M safe during breastfeeding?
Oflaquin M may lead to some side effects in breastfeeding women. If you witness any unusal symptoms after taking Oflaquin M, discontinue its use and call your doctor right away. Follow your doctor's advice regarding the use of Oflaquin M.
What is the effect of Oflaquin M on the Kidneys?
Very few cases of side effects of Oflaquin M on kidney have been reported.
What is the effect of Oflaquin M on the Liver?
Oflaquin M has very mild side effects on the liver.
What is the effect of Oflaquin M on the Heart?
Oflaquin M has very mild side effects on the heart.
Oflaquin M should not be taken with following medicines due to severe side effects it may cause to patients -
Life Threatening
Severe
Moderate
Mild
If you are suffering from any of the following diseases, you should not take Oflaquin M unless your doctor advises you to do so -
Is this Oflaquin M habit forming or addictive?
No, you will not get addicted to Oflaquin M.
Interaction between Food and Oflaquin M
It is safe to take Oflaquin M with food.
Interaction between Alcohol and Oflaquin M
Consumption of alcohol and Oflaquin M together may have severe effects on your health.
No, Oflaquin M does not contain penicillin. It is an antibiotic that belongs to the class of medication called fluoroquinolone. It used to treat several types of bacterial infection such as such as bronchitis, pneumonia, urinary, respiratory, skin, gastrointestinal, anthrax, bone, and eye infections.
Discontinuing Oflaquin M on your own can increase the chances of bacterial resistance and infection relapse. It is recommended that you always consult your doctor if you have decided to discontinue this medicine.
Oflaquin M is not recommended as the first-line of drug for treating sinus infection. However, if there are no other alternatives available then you can take it, after doctor's advice.
Yes, Oflaquin M can be taken with paracetamol, no clinically significant interactions are seen between these two. However, it doesn't mean that no interaction exists between them. Please talk to your doctor before consuming these two medicines at the same time.
Oflaquin M can be taken with doxycycline. No drug-drug interactions are reported between them. Doxycyclin also does not affect the absorption of this drug. However, it doesn't mean that no interaction could exist. Please consult your doctor, if you feel any complication after consuming these two medicines at the same time.
This medicine data has been created by -
References
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1400
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 713
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Floxin® (ofloxacin)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Ocuflox® (ofloxacin)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Flagyl® Metronidazole
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 837-839
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 850-851
